---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-254659"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2023-10-12T23:59:59+00:00"
generated_at: "2026-06-10T00:50:37.822111+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IN8bio starts Phase 2 GBM trial (INB-400) and completes Phase 1 dose escalation (INB-100)

## Summary
- Enrollment open for Phase 2 trial of INB-400 in newly diagnosed GBM; plans ~40 patients in Arm A; primary endpoint 12-month OS.
- Dose escalation phase of Phase 1 INB-100 trial in leukemia closed; clinical update expected at ASH Dec 9-12, 2023.
- As of April 2023, 100% of evaluable patients (n=7) on INB-100 in durable complete remission; one patient progression-free >3 years.
- First activated sites for INB-400: University of Louisville and Cleveland Clinic; INB-400 received FDA Orphan Drug Designation April 2023.
- R&D Day held October 12, 2023; webcast available.

## SEC filing metadata
- accession: 0001193125-23-254659
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2023-10-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000119312523254659/0001193125-23-254659-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000119312523254659/d535806d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-254659
- JSON: https://secwatch.observer/filing/0001193125-23-254659.json
- Plain text: https://secwatch.observer/filing/0001193125-23-254659.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.